News

The neurofibromatosis type 1 market remains niche, but awareness campaigns, increased diagnoses, and treatment adoption, along with ongoing clinical ...
As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...
We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...
We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...
FRANKFURT: German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 ...
FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for ...
Applied to medicines, price controls would translate into shortages and slow, or non-existent, introduction of new, ...
Merck KGaA led the way in pharmaceutical M&A in April. The German company announced a $3.9 billion deal to buy the US drug ...
Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...
Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.
Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.